The Centers for Disease Control and Prevention provides funding for HIV prevention for the populations at the highest risk of infection. State efforts to shift priorities could lead to poorer outcomes, more deaths and increased costs.
More data and research are needed about the impact of policies that shift funding for HIV prevention away from populations most at risk for infection, Allison Agwu, M.D., MSc, said during a presentation on Hot Topics in HIV at ID Week 2024, which is being held this week in Los Angeles.
Agwu, who is professor, pediatric and adult infectious diseases at Johns Hopkins University in Baltimore, presented an analysis done by Ethan Borre, M.D., Ph.D., at the Massachusetts General Hospital, that showed Tennessee’s plan to shift funding for HIV prevention could lead to poorer outcomes, more deaths and increased costs.
In January 2023, Tennessee rejected $6.2 million in funding from the Centers for Disease Control and Prevention (CDC) for HIV prevention. CDC provides funding for HIV testing kits, condoms and pre-exposure prophylaxis (PrEP) with a priority focused on men who have sex with men, transgender women, people who inject drugs and heterosexual black women. Instead, the state would reallocate separate funding for HIV testing for first responders, pregnant women and survivors of sex trafficking.
The analysis done by Massachusetts General Hospital used a model called the Cost-Effectiveness of Preventing AIDS Complications (CEPAC), which is a computer-based simulation model to predict outcomes for disease. Researchers teamed up with Tennessee-based community organizations Nashville CARES and Friends For All Memphis, as well as investigators from Vanderbilt University, Yale University, and the national HIV Medicine Association.
Borre and his colleagues found that reallocating HIV prevention funding away from CDC-prioritized populations toward would result in additional HIV transmissions and deaths, including 166 additional HIV transmissions, 190 additional deaths, and 843 life-years lost over 10 years. It will also lead to $4.1 million in costs, or a 1,300% increase in costs per death prevented among people with HIV.
The research was published in June 2024 in Clinical Infectious Diseases.
“CDC HIV prevention funding has prevented countless HIV cases and deaths in Tennessee, and throughout the United States, especially amongst those at highest risk for HIV, including men who have sex with men, transgender women and heterosexual Black women. Rejecting this funding puts lives at risk,” Borre said in a news release.
The populations prioritized by Tennessee are small, just 1% of the state’s population at risk for infection, Agwu said during the ID Week session. She pointed out that during the period 2018 to 2023, HIV rates in Tennessee increased 40% among 15 to 19 year olds, which is an at-risk population.
An epidemiology study released in May 2024 by the Tennessee Department of Health found that non-Hispanic Black people had the highest burden of HIV across all gender, age group, and transmission risk categories. And 14% of new diagnoses occurred among people who inject drugs. Among cisgender females newly diagnosed with HIV in 2022, heterosexual sexual contact was the most commonly reported transmission risk.
Researchers Massachusetts General Hospital said their projection was a conservative estimate. A more pessimistic estimate is an additional 1,359 HIV transmissions, 712 additional deaths, and 2,778 life-years lost over 10 years.
They said reallocating funds away for the CDC’s priorities would worsen health disparities for sexual/gender minoritized populations and people of color. Black men who have sex with men at the highest risk for HIV infection in Tennessee.
Agwu urged attendees to advocate for HIV funding focused on priority populations. “We are facing continuous attacks on HIV funding, and the progress that we're making with all the things we’re talking about here could potentially be a risk,” she said.
With Its Future in Doubt, One of the Architects Makes a Case for PEPFAR | IDWeek 2023
October 15th 2023Mark Dybul, M.D., the keynote speaker for the closing session of the IDWeek meeting in Boston, delivered an impassioned defense of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) as its reauthorization by Congress has got ensnarled in abortion issues.
Read More
Cytomegalovirus Update: For the First Time, a Phase 3 Vaccine Trial | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center spoke about the phase 3 trial of Moderna’s mRNA vaccine against CMV and another candidate being developed by Merck that showed some promise in a phase 2B trial.
Read More
Cytomegalovirus Update: Why Isn’t There a Vaccine? | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says lack of awareness and funding as well as some characteristics of the virus itself have slowed development of vaccine against CMV.
Read More
Cytomegalovirus Update: Congenital CMV Is a ‘Disease of Disparity’ | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says the epidemiology of congenital CMV hasn’t varied much over the years and that the condition does disproportionately affect lower socioeconomic populations and communities of color in the U.S.
Read More